Related Experiment Video
Updated: Aug 24, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Genetic predictive factors in restenosis
P S Monraats1, W R P Agema, J W Jukema
1Department of Cardiology, Leiden University Medical Center, C5-P, Albinusdreef 2, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Insights
Genetic factors may help predict restenosis after coronary angioplasty. Understanding these genetic variations could lead to personalized treatments for patients undergoing percutaneous transluminal coronary angioplasty.
Area of Science:
- Cardiovascular Genetics
- Interventional Cardiology
Background:
- Restenosis remains a significant complication of percutaneous transluminal coronary angioplasty (PTCA).
- The multifactorial nature of restenosis involves vessel recoil, neointimal proliferation, and thrombus formation.
- Predicting restenosis using clinical and procedural factors has been challenging.
Purpose of the Study:
- To review genetic variables and polymorphisms associated with restenosis.
- To explore the potential of genetic epidemiology in understanding and predicting restenosis.
- To discuss the implications of genetic stratification for personalized interventional treatment.
Main Methods:
- Review of published literature on genetic polymorphisms related to restenosis.
- Identification of single nucleotide polymorphisms (SNPs) in key pathways: renin-angiotensin system, platelet aggregation, inflammation, matrix metalloproteinases, smooth muscle cell proliferation, lipids, oxidative stress, and nitric oxide.
- Discussion of DNA-microarray technology for simultaneous polymorphism testing.
Main Results:
- Several genetic polymorphisms have been investigated in relation to restenosis.
- Studies often have small sample sizes, leading to potential publication bias and wide confidence intervals.
- The multifactorial nature suggests multiple genes contribute to restenosis risk.
Conclusions:
- Genetic epidemiology offers promising insights into restenosis.
- Interpreting genetic association studies requires caution due to methodological limitations.
- Future genetic stratification may enable tailored interventional strategies for individual patients.
Abstract:
Restenosis is still the main drawback of percutaneous transluminal coronary angioplasty (PTCA). It is thought to be a multifactorial process where recoil of the vessel, neointimal proliferation and thrombus formation are thought to play a role. Until now it has proven difficult to predict restenosis on clinical and procedural grounds, however, genetic epidemiology might provide more insights. In this review several genetic variables, i.e. polymorphisms that were determined in relation to restenosis are described. The single nucleotide polymorphisms (SNPs) described in the literature so far involve; the renin-angiotensin system, platelet aggregation, the inflammatory response, matrix metalloproteinases, smooth muscle cell proliferation, lipids and oxidative stress and nitric oxide. Nowadays DNA-microarrays have been developed which make it possible to test 50 or 60 polymorphisms at once. However, the risk of error due to multiple testing should be kept in mind. The results of the studies described should be interpreted with care. Many of the published studies are of relatively small sample size, which sometimes show more positive outcomes than the larger studies, this is possibly due to publication bias towards more positive results. The small sample size studies also exhibit wide confidence intervals. On the other hand, one must take into account that the process of restenosis is a multifactorial one and it is likely that multiple genes are involved. Thus, relatively small odds ratios relating to single gene contribution to restenosis can be of paramount importance when encompassed in the overall picture. Although still much research has to be done, stratification according to genetic make-up may enable tailoring of the interventional treatment to the individual patient.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase